JPMorgan bullish on Rollins as it sees long growth runway in pest control

JPMorgan initiated coverage on Rollins (ROL) with an Overweight rating and a $70 price target, projecting approximately 24% upside. The brokerage highlights Rollins' resilient business model, characterized by ~80% recurring revenue from service contracts, and its significant growth potential within the under-penetrated $20 billion U.S. pest control market. Analysts anticipate steady 7-8% annual organic growth, margin expansion to 25% EBITDA by 2027, and double-digit earnings growth over the next two years, with FY25/26 EPS forecasts 3-5% above consensus, supported by strategic acquisitions and operational efficiencies.

Analysis

JPMorgan has initiated coverage on Rollins, Inc. (ROL) with an Overweight rating and a $70 price target, signaling a potential 24% upside. The core of the bullish thesis rests on the company's resilient business model, where approximately 80% of revenue is derived from recurring service contracts, providing significant visibility and stability. The firm operates within a large and under-penetrated U.S. pest control market, valued at over $20 billion with only about 15% household adoption, offering a substantial runway for growth. JPMorgan projects steady organic growth of 7-8% annually, supported by modest pricing power and disciplined bolt-on acquisitions, which are expected to fuel double-digit earnings growth over the next two years. This outlook is underpinned by forecasts for fiscal 2025 and 2026 EPS that are 3-5% above consensus estimates. Furthermore, margin expansion is a key driver, with EBITDA margins anticipated to increase from the current 22-23% range to 25% by 2027, driven by productivity gains and improved technician retention. While Rollins trades at a premium valuation of approximately 30 times forward EBITDA, JPMorgan argues this is justified by its defensive recurring revenue, strong free cash flow generation, and conservative balance sheet.

Key Decisions for Investors

• Investors with a long-term growth and defensive focus may consider initiating or adding to positions in ROL, given the analyst's projection of double-digit earnings growth and a 24% upside to the $70 price target.
• Monitor key performance indicators central to the thesis, including organic revenue growth against the 7-8% target, progress on EBITDA margin expansion towards the 25% goal, and the pace and integration of bolt-on acquisitions.
• While the growth story is compelling, be mindful of the premium valuation at 30x forward EBITDA, which prices in strong execution and could make the stock vulnerable to any shortfalls in meeting growth or margin targets.